Pacira BioSciences (PCRX) Cash from Investing Activities Growth (1y) (2011 - 2026)
Pacira BioSciences (PCRX) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 13.93% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 57.14% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -186.78% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 551.55% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 526.11% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -3,664.79% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -3.45% |
| 10 | Pacira BioSciences | 1.08 Bn | 876.91 Mn | 140.96 Mn | 175.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 175.86% |
| Dec 31, 2025 | 5,353.53% |
| Sep 30, 2025 | 183.61% |
| Jun 30, 2025 | 508.56% |
| Mar 31, 2025 | -65.03% |
| Dec 31, 2024 | -104.39% |
| Sep 30, 2024 | -1,101.36% |
| Jun 30, 2024 | -307.68% |
| Mar 31, 2024 | -123.47% |
| Dec 31, 2023 | -25.16% |
| Sep 30, 2023 | 90.86% |
| Jun 30, 2023 | -61.77% |
| Mar 31, 2023 | 131.82% |
| Dec 31, 2022 | -83.28% |
| Sep 30, 2022 | -35.46% |
| Jun 30, 2022 | 531.75% |
| Mar 31, 2022 | -273.70% |
| Dec 31, 2021 | 181.29% |
| Sep 30, 2021 | 82.71% |
| Jun 30, 2021 | -91.60% |